Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- WLFC +6%, IMOS +3.6% (Feb sales), FNV +1.1%
Other news:
- RDFN +85.7% (Rocket Companies enters into agreement to acquire Redfin (RDFN) in all-stock transaction for $12.50 per Redfin share)
- CKPT +66.8% (to be acquired by Sun Pharma for upfront cash payment of $4.10 per share)
- TRVI +32.8% ( topline results from the Phase 2a RIVER trial of haduvio in patients with refractory chronic cough; to host a conference call and webcast today at 8:30 a.m. ET)
- MLYS +15.9% (announces positive topline results from launch-HTN and advance-HTN pivotal trials of lorundrostat for the treatment of uncontrolled or resistant hypertension)
- JBI +14.4% (announces $40 million debt paydown)
- VRN +12.2% (Veren and Whitecap Resources (SPGYF) to combine in an all-share transaction valued at approximately $15 billion, inclusive of net debt)
- BEAM +12.1% (Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency; prices offering of common stock and warrants)
- BECN +8.2% (QXO, Inc and Beacon Roofing Supply (BECN) confirm that they are in discussions about a potential combination in which QXO would acquire Beacon for $124.35 per share in cash, or total consideration of approximately $11 billion)
- LGTY +5% (receives unsolicited proposal for $15.00 per share)
- PERI +4.4% (authorizes expansion of share repurchase program)
- CTSH +4% (activist investor Mantle Ridge built an over $1 bln stake in the company, according to WSJ)
- DASH +3.7% (to join S&P 500)
- TKO +2.6% (to join S&P 500)
- EXE +2.1% (to join S&P 500)
- WSM +1.7% (to join S&P 500)
- INCY +1% (results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting)